Press Release

EVMPD software provider Pharma eReport announces full general availability of Centrality XEVMPD compliance solution

Centrality software is fully compliant with March 2012 EMA specification updates and available now to pharmaceutical Marketing Authorisation Holders

 

Cambridge, UK, March 21 2012 - Pharma eReport, a software and services company that delivers a comprehensive EVMPD compliance solution for pharmaceutical regulatory professionals, today announces that its Centrality software suite is now in full general availability, incorporating the latest specification changes from the European Medicines Agency (EMA) issued on 5th March 2012. The software has been fully tested to compliantly generate valid, syntactically-correct XML data. Prospective customers can sign up and register for the software online now.


Pharma eReport – a subsidiary of ELC Group, the pan-European pharmaceutical regulatory affairs organisation – offers a full service solution to help Marketing Authorisation Holders (MAHs) meet the July 2nd 2012 deadline for mandatory EudraVigilance Medicinal Product Dictionary (EVMPD/XEVMPD) data submissions. Pharma eReport’s flagship Centrality software suite and specialist EVMPD services – delivered by a Key Support Services team of qualified chemists – provide a comprehensive, quality-assured EVMPD compliance solution that is available to customers now.

Pharma eReport’s Centrality software allows MAHs to easily convert existing medicinal product information into an XML Schema Definition (XSD)-compliant format, and seamlessly upload the required data as a EudraVigilance Product Report Message (EVPRM) using an approved submission mechanism. All software database elements as well as the XML output are directly driven from officially mandated EMA schema, and subject to stringent testing and QA procedures. The software is secure, easy to use and custom-engineered for flexible implementation, including development support for bespoke interfaces to provide full harmonisation with customers’ existing systems. Centrality allows the import and export of XML and CSV files, enabling total ease of integration with all existing enterprise and pharmaceutical regulatory software platforms and product life cycle management systems.

The Centrality software is offered via a transparent pricing model and with fully flexible deployment options. The Centrality platform is available as a secure, on-demand cloud-based application (Software-as-a-service) accessed via a standard web browser, or it can be installed as a standalone software application. For customers who wish to have all their data in-house, Centrality can be installed on a company intranet, so that the data is held on-site and authorised users can access it securely via the company system. The Centrality software solution is completely independent – no other software needs to be installed – and offers full support for both Windows and Linux.

Pharma eReport also provides a full range of Key Support and consulting service, including data collation, organisation and mapping capabilities, to help customers meet any challenge related to EVMPD implementation and ensure timely compliance with the EMA mandate.

Commenting on today’s announcement, Marco Rubinstein, CEO of Pharma eReport said: "We are delighted to be launching our Centrality software into full general availability today. Now is the critical time period for Marketing Authorisation Holders to select a software partner to help them meet the July 2012 EVMPD compliance deadline and we’ve worked hard to ensure that our Centrality solution is easy-to-use, fully compliant, secure and future-proof, offering the highest quality assurance and the best solution possible for our customers.” He continued: “The schema-derived nature of our platform means that any EMA specification changes – and, indeed, any intermediate schemes ahead of the planned ISO IDMP (Identification of Medicinal Products) standard – can be quickly and seamlessly incorporated into our platform. We’ve designed Centrality from the ground up to provide a total solution for managing ongoing, database-wide pharmacovigilance updates and ensuring continuing EMA regulatory compliance. We’re looking forward to helping our customers meet the short-term EVMPD compliance challenge and continuing to support them in a long-term, successful partnership.”

To sign-up online and become a registered user of Pharma eReport’s Centrality software, please visit: http://www.pharmaereport.com

---ends---

Press contacts
Nicky Denovan
Pharma eReport
nicky [at] pharmaereport [dot] com
Phone: +44 (0) 7747 017654

About Pharma eReport (http://www.pharmaereport.com)
Cambridge, UK-based Pharma eReport provides intuitive electronic product data management and reporting software for pharmaceutical regulatory professionals.

With its flagship Centrality software suite and supporting specialist EVMPD services – delivered by a Key Support Services team of qualified chemists – Pharma eReport provides a comprehensive EVMPD solution, including complete outsourced data collation, organisation and mapping capabilities. The Centrality software is available as an on-demand software-as-a-service (SaaS)/cloud-based solution – accessed via a standard web browser – or it can be installed as a standalone software application at a client site.

Pharma eReport is co-founded by the management of ELC Group – a leading global services company with recognised expertise in regulatory affairs and Marketing Authorisation management – plus former executives from electronic design automation software company Synopsys, Inc. Pharma eReport harnesses the unparalleled industry knowledge of its regulatory expert founders and combines this with a world-class software development team to deliver a total solution for EVMPD compliance and beyond.


Please let us know any comments you have on this article:

Also see our

press coverage

News Index

05 Oct 2018

EU/US MRA - Brief overview and update

21 Aug 2018

Brexit - has the music stopped?

13 Jul 2018

Recent EMA Brexit Survey

15 Jun 2018

The EMA: 100 not out

08 May 2018

MHRA sets its post-Brexit strategic direction

12 Apr 2018

Brexit - Stick or Twist?

20 Mar 2018

Clinical Trials: all change 2019

22 Jan 2018

Orphan Medicines: almost 20 years on

15 Dec 2017

Update on Brexit developments

05 Oct 2017

How recent moves by the FDA spell good news for generics in the US

11 Sep 2017

Medicines for the Elderly – is your drug development strategy up to the mark?

14 Aug 2017

The MNAT initiative – what’s new?

19 Jul 2017

ICH Q12: Light at the end of the tunnel…?

05 Jun 2017

Q3D: Are your established products in compliance?

02 Jun 2017

Key pharmacovigilance trends to watch

08 May 2017

EMA updates guidance on PSURs

10 Apr 2017

New EMA Consultation on the Quality of Inhaled Pharmaceutical Products

16 Mar 2017

European Parliament’s adoption of ‘Options for improving access to medicines’ procedure

16 Feb 2017

Article 58: a hidden potential

24 Jan 2017

Global lifesciences partner ELC Group teams with PSR Group for advanced drug development

19 Jan 2017

A positive step forward for Biosimilar registration

20 Dec 2016

Falsified Medicines Directive – Are you making the right preparations?

21 Nov 2016

New Public consultation launched by the European Commission (EC)

19 Oct 2016

Transatlantic collaboration to boost research and development of medicines for rare diseases

03 Jun 2016

ELC Group to showcase regulatory affairs solutions at CPhI events in Shanghai and Barcelona

16 Jun 2015

ELC Group in early-stage development of novel influenza vaccine

09 Jun 2015

ELC Group expands into pharmaceutical product development market

21 Apr 2015

ELC Group signs 1.5 million Euro regulatory affairs contract with Chinese pharma giant

24 Feb 2015

Fast-growing regulatory affairs service provider ELC Group expands corporate presence in Czech Republic

02 Feb 2015

ELC GROUP to present at “Regulatory & Legal Affairs in Russia 2015” Conference

15 Sep 2014

Pharma eReport delivers V5-compliant solution to help MAHs meet December 31st XEVMPD resubmission deadline

20 Aug 2014

ELC Group Appoints Dr. Siddharth Chachad as Head of Global Clinical Development and Medical Affairs

28 Jul 2014

ELC Group Appoints Head of Regulatory Affairs for Russia and CIS

14 Apr 2014

Global regulatory affairs specialist ELC Group appoints Localization Business Development Manager for new US Office

10 Oct 2013

Global regulatory affairs specialist ELC Group accelerates international expansion plans following 25% revenue growth in 2013

17 Sep 2013

Global regulatory affairs specialist ELC Group appoints former MHRA Expert Medical Assessor

23 Apr 2013

Global regulatory affairs specialist ELC Group receives accreditation to provide readability testing in Romania

27 Feb 2013

Global regulatory affairs specialist ELC Group to deliver pharmaceutical training event in Latvia

20 Feb 2013

Global pharmaceutical regulatory affairs specialist ELC Group launches Clinical Trials services

10 Jan 2013

Global pharmaceutical regulatory affairs specialist ELC Group hosts International Training Seminar in Mumbai, India

31 Dec 2012

2012 Events

07 Nov 2012

Global pharmaceutical regulatory affairs specialist ELC Group establishes new office in Singapore

22 Aug 2012

Global pharmaceutical regulatory affairs specialist ELC Group increases operational support in Ahmedabad

12 Jun 2012

XEVMPD software provider Pharma eReport launches Excel Data Import Service

06 Jun 2012

ELC Group partners with mdi Europa GmbH to offer end-to-end regulatory solution for medical device companies in Europe

28 Mar 2012

ELC Group joins DIA EuroMeeting in Copenhagen

21 Mar 2012

EVMPD software provider Pharma eReport announces full general availability of Centrality XEVMPD compliance solution

08 Mar 2012

ELC Group Hosts Successful International Regulatory Seminar

06 Mar 2012

Pharmaceutical regulatory affairs specialist ELC Group opens new office in Mumbai

23 Feb 2012

Regulatory challenges for 2012 and their impact on marketing authorisation

21 Feb 2012

ELC Group launches new software subsidiary Pharma eReport to provide complete EVMPD compliance solution

08 Feb 2012

Pharmaceutical regulatory affairs specialist ELC Group establishes global HQ in Cambridge, UK

07 Dec 2011

Past president of TOPRA and ELC GROUP Advisor speaks at International Regulatory Seminar in Ahmedabad 23 February 2012

27 Sep 2011

ELC GROUP Advisory Board’s Dr. Paolo Biffignandi to write opinion column for industry leading publication

12 Jul 2011

ELC Group aim to foster strategic and economic ties within India and China

25 May 2011

ELC Group announces doubled revenues

11 May 2011

ELC Group appoints former TOPRA President